Martin Victor, Bettencourt Ana
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Portugal.
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Portugal.
Mater Sci Eng C Mater Biol Appl. 2018 Jan 1;82:363-371. doi: 10.1016/j.msec.2017.04.038. Epub 2017 Apr 11.
Bone is a mineralized conjunctive tissue, with a unique trauma healing capability. However, the replacement or regeneration of lost bone is not always successful and becomes more difficult the wider the bone defect. A significant growth in the demand for orthopedic and maxillofacial surgical procedures as a result of population aging and increase in chronic diseases as diabetes is a fact and successful approaches for bone regeneration are still needed. Until today, autogenous bone graft continues to be the best solution even with important limitations, as quantity and the requirement of a donator area. Alternatively, local delivery systems combining an osteoconductive biomaterial with osteoinductive compounds as hormones, growth factors or drugs is a popular approach aiming to replace the need for autogenous bone grafts. Nevertheless, in spite of the intense research in the area, presently there is no system that can mimic all the biological functions of the autogenous bone grafts. In this context, the present work provides an overview of the most recent advances in the field of synthetic bone grafts. The opportunities and limitations are detailed along with the remaining gaps in the research that are still preventing the successful translation of more products into the market able to be a valuable option in comparison to the autogenous bone grafts.
骨是一种矿化的结缔组织,具有独特的创伤愈合能力。然而,缺失骨的替代或再生并不总是成功的,骨缺损越宽,难度就越大。由于人口老龄化以及糖尿病等慢性疾病的增加,骨科和颌面外科手术的需求显著增长,这是一个事实,而骨再生的成功方法仍有待探索。直到今天,自体骨移植仍然是最佳解决方案,即便存在诸如数量限制和供体区域需求等重要局限性。另外,将骨传导生物材料与骨诱导化合物(如激素、生长因子或药物)相结合的局部递送系统是一种旨在取代自体骨移植需求的常用方法。尽管如此,尽管该领域进行了深入研究,但目前尚无能够模拟自体骨移植所有生物学功能的系统。在此背景下,本研究概述了合成骨移植领域的最新进展。详细介绍了其机遇与局限,以及研究中仍存在的差距,这些差距仍阻碍着更多产品成功转化为市场上的产品,使其无法成为与自体骨移植相比有价值的选择。